SSS 40
Alternative Names: SSS-40; SSS-40-anti-NGF AbLatest Information Update: 29 Apr 2024
At a glance
- Originator 3SBio
- Class Antibodies; Eye disorder therapies
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Eye disorders
Most Recent Events
- 02 Apr 2024 Preclinical trials in Autoimmune disorders in China (unspecified route) (3SBio pipeline, April 2024)
- 02 Apr 2024 Preclinical trials in Eye disorders in China (unspecified route) (3SBio pipeline, April 2024)